Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 12/20 | 0.54 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.54 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.54 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 2/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | PREP | P48147 | 2/20 | 0.41 |
| ▸ | FAP | Q12884 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30439280 | 0.83 | PREP (0.56) | DPP4SMN1; SMN2F2PRSS1PREP | |
| SCHEMBL28578875 | 0.83 | PREP (0.46) | DPP4F2PREPFAPCYP2C19 | |
| SCHEMBL29985759 | 0.81 | PREP (0.44) | DPP4DPP8DPP9F2PRSS1 | |
| SCHEMBL8564779 | 0.80 | DPP4 (0.46) | DPP4DPP8DPP9DPP7SMN1; SMN2 | |
| SCHEMBL8564777 | 0.80 | DPP4 (0.46) | DPP4DPP8DPP9DPP7SMN1; SMN2 | |
| SCHEMBL26391683 | 0.80 | PREP (0.59) | DPP4F2PREPFAPLMNA | |
| SCHEMBL30439075 | 0.80 | P2RX7 (0.49) | SMN1; SMN2F2CYP2C19 | |
| SCHEMBL9139264 | 0.80 | PREP (0.48) | DPP4SMN1; SMN2F2PREPFAP | |
| SCHEMBL29240007 | 0.79 | ALDH1A1 (0.42) | DPP4SMN1; SMN2PREPFAPPOLB | |
| SCHEMBL1509573 | 0.79 | DPP4 (0.49) | DPP4DPP8DPP9DPP7POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675578-B9 | INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES FOR THE TREATMENT OF THE NEURODEGENERATIVE DISEASES FBD AND FDD | PROBIODRUG AG (DE) | 2014-06-25 | — | — | EP | claimed |
| US-8470781-B2 | Use of effectors of glutaminyl and glutamate cyclases | PROBIODRUG AG (DE) | 2013-06-25 | — | — | US | claimed |
| EP-1675578-B1 | INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES FOR THE TREATMENT OF THE NEURODEGENERATIVE DISEASES FBD AND FDD | PROBIODRUG AG (DE) | 2013-05-22 | — | — | EP | claimed |
| EP-2289498-A1 | Use of inhibitors of glutaminyl clyclase | Probiodrug AG (DE) | 2011-03-02 | — | — | EP | claimed |
| EP-1620082-B9 | MEDICAL USE OF INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES FOR TREATING ALZHEIMER'S DISEASE AND DOWN SYNDROME | PROBIODRUG AG (DE) | 2010-08-25 | — | — | EP | claimed |
| EP-2206496-A1 | Medical use of inhibitors of glutaminyl and glutamate cyclases | Probiodrug AG (DE) | 2010-07-14 | — | — | EP | claimed |
| EP-1620082-B1 | MEDICAL USE OF INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES FOR TREATING ALZHEIMER'S DISEASE AND DOWN SYNDROME | PROBIODRUG AG (DE) | 2010-04-21 | — | — | EP | claimed |
| US-20090149394-A1 | USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES | PROBIODRUG AG (DE) | 2009-06-11 | — | — | US | claimed |
| US-7462599-B2 | Use of effectors of glutaminyl and glutamate cyclases | PROBIODRUG AG (DE) | 2008-12-09 | — | — | US | claimed |
| EP-1961416-A1 | Medical use of inhibitors of glutaminyl and glutamate cyclases | Probiodrug AG (DE) | 2008-08-27 | — | — | EP | claimed |
| US-7381537-B2 | Use of inhibitors of glutaminyl cyclases for treatment and prevention of disease | PROBIODRUG AG (DE) | 2008-06-03 | — | — | US | claimed |
| US-20060189523-A1 | Use of effectors of glutaminyl and glutamate cyclases | PROBIODRUG AG (DE) | 2006-08-24 | — | — | US | claimed |
| US-8470781-B2 | Use of effectors of glutaminyl and glutamate cyclases | PROBIODRUG AG (DE) | 2013-06-25 | — | — | US | disclosed |
| EP-1961416-B1 | Use of inhibitors of glutaminyl cyclase for treating psoriasis, rheumatoid arthritis or atherosclerosis. | PROBIODRUG AG (DE) | 2013-01-23 | — | — | EP | disclosed |
| EP-2289498-A1 | Use of inhibitors of glutaminyl clyclase | Probiodrug AG (DE) | 2011-03-02 | — | — | EP | disclosed |
| US-7897633-B2 | Neuronal disorders such as Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function; alcoholism | PROBIODRUG AG (DE) | 2011-03-01 | — | — | US | disclosed |
| US-20050107308-A1 | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels | PROSIDION LIMITED (GB) | 2005-05-19 | — | — | US | disclosed |
| US-6890905-B2 | Methods for improving islet signaling in diabetes mellitus and for its prevention | PROSIDION LIMITED (GB) | 2005-05-10 | — | — | US | disclosed |
| US-20050058635-A1 | Anticancer agents; therapy for infections; administering glutaminyl cyclase inhibitor; Alzheimer's disease; Down syndrome; controlling fertility; schizophrenia; skin disorders | PROBIODRUG AG (DE) | 2005-03-17 | — | — | US | disclosed |
| US-20040224875-A1 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107308-A1 | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels | DPP4, DPP3, DPP9 | DPP4 1/4885DPP8 4/4885DPP9 3/4885 |
| US-20060189523-A1 | Use of effectors of glutaminyl and glutamate cyclases | GLS, GLUL, GLS2 | DPP4 1981/4885DPP8 3636/4885DPP9 2668/4885 |
| US-20090149394-A1 | USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES | GLS, GLUL, GLS2 | DPP4 1981/4885DPP8 3636/4885DPP9 2668/4885 |
| US-20040224875-A1 | Inhibitors of glutaminyl cyclase | GLS2, GLS, GLUL | DPP4 2056/4885DPP8 2739/4885DPP9 1376/4885 |
| US-20050058635-A1 | Anticancer agents; therapy for infections; administering glutaminyl cyclase inhibitor; Alzheimer's disease; Down syndrome; controlling fertility; schizophrenia; skin disorders | GLS, QPCT, GLS2 | DPP4 564/4885DPP8 1336/4885DPP9 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.